| Chronic Obstructive Airway Disease
Bevespi Aerosphere vs Stiolto Respimat
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Bevespi Aerosphere vs Stiolto Respimat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStiolto Respimat has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stiolto Respimat but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bevespi Aerosphere
Stiolto Respimat
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
Oral inhalation
Once daily
LAMA/LABA
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Contraindications
- Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Bevespi Aerosphere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Bevespi Aerosphere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
No savings programs available for Stiolto Respimat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
Stiolto RespimatView full Stiolto Respimat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.